NasdaqGM:EDAP

Stock Analysis Report

Executive Summary

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide.

Snowflake

Fundamentals

Reasonable growth potential with adequate balance sheet.

Risks

  • EDAP TMS has significant price volatility in the past 3 months.
  • EDAP TMS is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has EDAP TMS's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

10.8%

EDAP

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

58.6%

EDAP

9.9%

US Medical Equipment

0.6%

US Market

EDAP outperformed the Medical Equipment industry which returned 9.5% over the past year.

EDAP outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

EDAPIndustryMarket
7 Day10.8%1.1%-0.6%
30 Day39.1%0.6%2.2%
90 Day75.2%2.9%1.1%
1 Year58.6%58.6%10.8%9.9%2.9%0.6%
3 Year53.5%53.5%70.1%64.9%44.6%35.2%
5 Year220.6%220.6%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is EDAP TMS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

Is It Time To Consider Buying EDAP TMS S.A. (NASDAQ:EDAP)?

Valuation

Is EDAP TMS undervalued based on future cash flows and its price relative to the stock market?

58.17x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for EDAP TMS to establish if it is available at moderate discount.

Unable to calculate intrinsic value for EDAP TMS to establish if it is available at substantial discount.


Price Based on Earnings

EDAP TMS is overvalued based on earnings compared to the US Medical Equipment industry average.

EDAP TMS is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

EDAP TMS is poor value based on expected growth next year.


Price Based on Value of Assets

EDAP TMS is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is EDAP TMS expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

26.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

EDAP TMS's revenue is expected to grow by 8.9% yearly, however this is not considered high growth (20% yearly).

EDAP TMS's earnings are expected to grow significantly at over 20% yearly.

EDAP TMS's revenue growth is expected to exceed the United States of America market average.

EDAP TMS's earnings growth is expected to exceed the United States of America market average.

EDAP TMS's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if EDAP TMS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has EDAP TMS performed over the past 5 years?

13.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

EDAP TMS's year on year earnings growth rate has been positive over the past 5 years.

EDAP TMS has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

EDAP TMS has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

EDAP TMS has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

EDAP TMS used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

EDAP TMS's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is EDAP TMS's financial position?


Financial Position Analysis

EDAP TMS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

EDAP TMS's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

EDAP TMS's level of debt (22.1%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (27.3% vs 22.1% today).

Debt is not well covered by operating cash flow (3.2%, less than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 3x annual interest expense, ideally 3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 7.3x debt.


Next Steps

Dividend

What is EDAP TMS's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate EDAP TMS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate EDAP TMS's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as EDAP TMS has not reported any payouts.

Unable to verify if EDAP TMS's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as EDAP TMS has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of EDAP TMS's salary, the management and board of directors tenure and is there insider trading?

10.3yrs

Average board tenure


CEO

Marc Oczachowski (49yo)

12.5yrs

Tenure

0

Mr. Marc Oczachowski has been Chief Executive Officer of EDAP TMS SA since March 31, 2007 and its Executive Director since July 1, 2017. Mr. Oczachowski serves as the President of EDAP TMS France SAS and E ...


Board Age and Tenure

10.3yrs

Average Tenure

71yo

Average Age

The average tenure for the EDAP TMS board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Blandine Confort

    Investor Relations Officer and Secretary

    • Tenure: 0yrs
  • Marc Oczachowski (49yo)

    CEO & Executive Director

    • Tenure: 12.5yrs
  • Franois Dietsch (43yo)

    Chief Financial Officer

    • Tenure: 4.2yrs

Board Members

  • Argil Wheelock (71yo)

    Independent Director

    • Tenure: 10.3yrs
  • Philippe Chauveau (83yo)

    Chairman of the Board

    • Tenure: 22.4yrs
  • Pierre Beysson (77yo)

    Independent Director

    • Tenure: 17yrs
  • Rob Michiels (69yo)

    Independent Director

    • Tenure: 10.2yrs
  • Marc Oczachowski (49yo)

    CEO & Executive Director

    • Tenure: 12.5yrs

Company Information

EDAP TMS S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EDAP TMS S.A.
  • Ticker: EDAP
  • Exchange: NasdaqGM
  • Founded: 1979
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$131.070m
  • Shares outstanding: 29.00m
  • Website: https://www.edap-tms.com

Number of Employees


Location

  • EDAP TMS S.A.
  • Parc d’Activites la Poudrette-Lamartine
  • 4/6, rue du Dauphiné
  • Lyon
  • Rhône-Alpes
  • 69120
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EDAPNasdaqGM (Nasdaq Global Market)YesADS EACH REPR 1 ORD SHARE FRF0.8USUSDAug 1997
EDADB (Deutsche Boerse AG)YesADS EACH REPR 1 ORD SHARE FRF0.8DEEURAug 1997

Biography

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide.  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:34
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.